# Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

> **NCT02512042** · PHASE3 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 973 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Test-Brinzolamide 1% Ophthalmic suspension
- **DRUG:** Reference-Brinzolamide 1% Ophthalmic suspension

## Key facts

- **NCT ID:** NCT02512042
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 973 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512042, "Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02512042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*